Development of the epigenetic treatment against inflammatory bowel disease with targeting chromatin remodeling
Development of the epigenetic treatment against inflammatory bowel disease with targeting chromatin remodeling
批准号:
17590661
负责人:
ARIMURA Yoshiaki
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1.Examination of therapeutic effect in the mouse experimental colitisA single or combination administration of DNA methylation inhibitor (Aza-dC) and histone deacetylase (HDAC) inhibitor (FK228) was evaluated on therapeutic efficacy for the mouse DSS colitis.Colitis was induced by 3% DSS for four days ad libitum in Balb/c mouse.We divided it into our groups : DNA methylation inhibitor (Aza-dC) single administration group, HDAC inhibitor (FK228) single administration group, combined administration group, and control group and we explored the preventive and therapeutic effect of treatment.As a result, colitis rather accepted a tendency to worsen in an Aza-dC single administration group, while colitis was ameliorated in the combination group, which did not reach a statistically significant difference comparing with the control group, but preventive and therapeutic effect of treatment in FK228 group was proven.We next examined mouse TNBS colitis, where significant preventive and therapeutic effect of treatment in FK228 group was only demonstrated in DSS colitis.2.The in vivo analysis of the anti-inflammatory action mechanism of HDAC inhibitorWe reviewed various cytokine profiles using colonic tissue in the mouse TNBS colitis by ELISA.As a result, TNFα, IFN-γ, and IL-6 expression was decreased in a dose-dependent manner, but a significant difference was not found in IL-10 expression level.Furthermore, we isolated lamina propria lymphocytes (LPMC) from DSS colitis, and acetylation of H3 was detected in a FK228 dose-dependent manner revealed by Western blotting using an anti acetyl-histone (H3) antibody.3.Examination of the epigenetic abnormality in the experimental colitisWe genome-widely analyze gene expression changes with the chemical administration by cDNA array, and candidate genes whose silencing is canceled and expressing are going to be checked the chromatin remodeling state of the promoter region of those in future.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1097/00054725-200608000-00013
发表时间:
2006-08-01
期刊:
INFLAMMATORY BOWEL DISEASES
影响因子:
4.9
作者:
[Goto, Akira, Arimura, Yoshiaki, Hinoda, Yuji]
通讯作者:
Hinoda, Yuji
DOI:
10.1002/path.1978
发表时间:
2006-07-01
期刊:
JOURNAL OF PATHOLOGY
影响因子:
7.3
作者:
[Kobayashi, K., Arimura, Y., Imai, K.]
通讯作者:
Imai, K.
DOI:
10.1111/j.1365-2036.2005.02443.x
发表时间:
2005-05-01
期刊:
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
影响因子:
7.6
作者:
[Okahara, S, Arimura, Y, Imai, K]
通讯作者:
Imai, K
Development of stem cell therapy for colitis and colitis-associated carcinogenesis
-
批准号:21590819
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2009
-
负责人:ARIMURA Yoshiaki
-
依托单位:
海外基金